• New Partnership Announced to Deliver New Bioequivalence Solution for Pharmaceutical and Contract Research Organisations

News & Views

New Partnership Announced to Deliver New Bioequivalence Solution for Pharmaceutical and Contract Research Organisations

Jun 22 2007

Thermo Fisher Scientific Inc., announces a new strategic partnership with Megaware, a life science technology organisation, to deliver a new bioanalysis/equivalence solution and joint support services for pharmaceutical, biotech and Contract Research Organizations (CROs).

Under the terms of the collaboration, Thermo Fisher and Megaware will market a new comprehensive end-to-end software solution which provides bioequivalence functionality on a single platform to help speed up and manage clinical trials. Rapid market growth in generic drug production is driving the requirement for fast efficient bioequivalence studies to meet FDA ANDA guidelines (Abbreviated New Drug Applications). A unified software solution will aggregate disparate software systems for organizations that demand tools to speed service and management of this critical and regulated IPO.

The two companies will work together closely to target the market for bioanalysis/equivalence studies, initially in India and thereafter across the Far East and other markets. The market in India for clinical trials is growing rapidly, because the average cost of trials is significantly lower than in the United States and Europe. The consultancy firm McKinsey estimates that US and European pharmaceutical companies will spend US $1.5 billion per year on clinical trials in India by 2010.

Thermo Fisher and Megaware will jointly sell, market and support the new solution in the field. Thermo Fisher will bring its bioanalytical expertise to the partnership and Megaware, with headquarters in Westborough, MA and Mumbai, India, will deliver the end-to-end technological focus combined with on-the-ground market knowledge. The new solution will offer higher throughput, greater levels of compliance and standardisation of bioequivalence processes.

Digital Edition

Lab Asia 29.6 Dec

November 2022

In This Edition Chromatography Optimising Viral Vector Purification Strategies with Multimodal Chromatography Key UHPLC Characteristics Required for High throughput LC-MS New Low Volum...

View all digital editions

Events

SPIE Photonex

Dec 06 2022 Birmingham, UK

CPhI & P-MEC China 2022 - NEW DATES

Dec 20 2022 Shanghai, China & Online 21 November 2022 to 13 January 2023

Smart Factory Expo 2023

Jan 25 2023 Tokyo, Japan

Arab Health

Jan 30 2023 Dubai, UAE

Nano Tech 2023

Feb 01 2023 Tokyo, Japan

View all events